Literature DB >> 34244013

Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.

Steffani R Bailey1, Jennifer A Lucas2, Heather Angier2, Rebecca E Cantone2, Joan Fleishman2, Brian Garvey2, Deborah J Cohen2, Rebecca E Rdesinski2, Leah Gordon2.   

Abstract

INTRODUCTION: Buprenorphine, a medication for opioid use disorder (OUD), can be administered within primary care; however, little is known about characteristics associated with retention on buprenorphine in these settings. This study examines patient correlates of buprenorphine retention and whether an integrated, interdisciplinary treatment model (buprenorphine and behavioral health) is associated with higher odds of buprenorphine retention than a primarily medication-only treatment model.
METHODS: Electronic health record data from adult patients with an OUD, ≥1 buprenorphine order and ≥1 visit to either of two primary care clinics between 9/2/2014-6/27/2018 were extracted (N = 494 patients). Two research team members reviewed the medication start and stop dates for each buprenorphine order and classified as retained (≥6 months of orders) or not retained (<6 months of orders). Logistic regressions estimated the odds of retention on buprenorphine by 1) patient characteristics and 2) timing of patient's engagement in buprenorphine treatment (pre- or post-implementation of an integrated treatment model).
RESULTS: Of the study sample, 53% had ≥6 months of buprenorphine orders. Almost two times higher odds of retention were found among patients with ≥1 psychiatric comorbidity (versus none) and among those with buprenorphine orders in the post- versus pre-period.
CONCLUSIONS: An integrated, interdisciplinary model of OUD treatment was associated with ≥6 months of buprenorphine orders among our study population. Continued research is needed in real-world primary care settings to understand the impact of OUD treatment models on patient outcomes. A more nuanced examination of the associations between psychiatric diagnoses and buprenorphine treatment retention is warranted.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Medication for opioid use disorder; Opioid use disorder; Retention

Mesh:

Substances:

Year:  2021        PMID: 34244013      PMCID: PMC8664960          DOI: 10.1016/j.jsat.2021.108548

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  39 in total

1.  Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.

Authors:  Ajay Manhapra; Edeanya Agbese; Douglas L Leslie; Robert A Rosenheck
Journal:  Psychiatr Serv       Date:  2018-04-16       Impact factor: 3.084

2.  Development of a Cascade of Care for responding to the opioid epidemic.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson
Journal:  Am J Drug Alcohol Abuse       Date:  2019-01-24       Impact factor: 3.829

3.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

4.  Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.

Authors:  Ajay Manhapra; Ismene Petrakis; Robert Rosenheck
Journal:  Am J Addict       Date:  2017-05-04

5.  Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.

Authors:  Peter Hjelmström; Elin Banke Nordbeck; Fredrik Tiberg
Journal:  Drug Dev Ind Pharm       Date:  2020-01-08       Impact factor: 3.225

6.  Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Authors:  T V Parran; C A Adelman; B Merkin; M E Pagano; R Defranco; R A Ionescu; A G Mace
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

Review 7.  Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review.

Authors:  Maykel Farag Ghabrash; Arash Bahremand; Martine Veilleux; Geneviève Blais-Normandin; Gabrielle Chicoine; Catherine Sutra-Cole; Navdeep Kaur; Daniela Ziegler; Simon Dubreucq; Louis-Christophe Juteau; Laurent Lestage; Didier Jutras-Aswad
Journal:  J Dual Diagn       Date:  2020-02-23

8.  Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.

Authors:  Janet M Soeffing; L David Martin; Michael I Fingerhood; Donald R Jasinski; Darius A Rastegar
Journal:  J Subst Abuse Treat       Date:  2009-06-23

9.  Mental Health and Psychosocial Needs of Patients Being Treated for Opioid Use Disorder in a Primary Care Residency Clinic.

Authors:  Stephanie A Hooker; Michelle D Sherman; Mary Lonergan-Cullum; Adam Sattler; Bruce S Liese; Kathryn Justesen; Tanner Nissly; Robert Levy
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

10.  Retention of patients in opioid substitution treatment: A systematic review.

Authors:  Aisling Máire O'Connor; Gráinne Cousins; Louise Durand; Joe Barry; Fiona Boland
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

View more
  1 in total

1.  Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting.

Authors:  Mary M Sweeney; Laura Prichett; Michael I Fingerhood; Denis Antoine; Annie Umbricht; Kelly E Dunn; Megan E Buresh
Journal:  Am J Addict       Date:  2022-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.